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Background: Oleamide (ODA) is a fatty acid primary amide first identified in the cerebrospinal fluid of sleep-
deprived cats, which exerts effects on vascular and neuronal tissues, with a variety of molecular targets including
cannabinoid receptors and gap junctions. It has recently been reported to exert a hypolipidemic effect in hamsters.
Here, we have investigated the nuclear receptor family of peroxisome proliferator-activated receptors (PPARs) as
potential targets for ODA action.
Results: Activation of PPARα, PPARβ and PPARγ was assessed using recombinant expression in Chinese hamster
ovary cells with a luciferase reporter gene assay. Direct binding of ODA to the ligand binding domain of each of
the three PPARs was monitored in a cell-free fluorescent ligand competition assay. A well-established assay of
PPARγ activity, the differentiation of 3T3-L1 murine fibroblasts into adipocytes, was assessed using an Oil Red O
uptake-based assay. ODA, at 10 and 50 μM, was able to transactivate PPARα, PPARβ and PPARγ receptors. ODA
bound to the ligand binding domain of all three PPARs, although complete displacement of fluorescent ligand was
only evident for PPARγ, at which an IC50 value of 38 μM was estimated. In 3T3-L1 cells, ODA, at 10 and 20 μM,
induced adipogenesis.
Conclusions: We have, therefore, identified a novel site of action of ODA through PPAR nuclear receptors and
shown how ODA should be considered as a weak PPARγ ligand in vitro.
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Oleamide (ODA, (Z)-octadec-9-enamide) is a fatty acid pri-
mary amide first identified as an endogenous lipoamide in
the cerebrospinal fluid of sleep-deprived cats [1]. The ODA
biosynthesis pathway has not been intensively investigated,
but it has been hypothesised to involve the peptidyl glycine
α-amidating monooxygenase [2]. Alternatively, Driscoll
et al. [3] suggested that cytochrome c may also be a route
for ODA synthesis. ODA catabolism appears to be primar-
ily due to hydrolysis by fatty acid amide hydrolase
(FAAH) to oleic acid and ammonia [2,4]. More recently,* Correspondence: steve.alexander@nottingham.ac.uk; andrew.bennett@
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reproduction in any medium, provided the ora second hydrolase, restricted to a limited number of
higher mammals, named FAAH-2 with overlapping, but
distinct, tissue distribution has been discovered, at
which ODA appears to be the preferred substrate [5].
In vivo administration of ODA has a variety of observ-
able effects: as a sleep-inducing factor [6], also eliciting
hypothermia, analgesia and hypo-locomotion [7].
Extended dietary administration of ODA in vivo caused
hypolipidemia in high fat-fed hamsters through an
undetermined mechanism [8]. In vitro, ODA has also been
reported to induce vasorelaxation in the rat small mesen-
teric artery [9]. While the biological effects of ODA are
well documented, the molecular mechanisms and site of
action remain elusive. In vitro, ODA can inhibit gap junc-
tion formation [10], modulate GABA [11] and 5-HT [12]
receptors and bind to CB1 cannabinoid receptors [13].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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subfamily of nuclear receptors, which function as ligand-
activated transcription factors [14,15]. There are three dif-
ferent PPAR isotypes, PPARα, PPARβ or PPARγ [16]
encoded by distinct genes and linked to lipid metabolism
and glucose homeostasis, as well as inflammation and
cytoprotection. Endogenous ligands for PPARs include
fatty acids and their metabolites, including prostaglan-
dins and leukotrienes [14,15]. A variety of cannabinoids
and related molecules have been reported to bind and
activate PPARs and at least some of their actions might
be explained by this interaction [17,18]. We hypothesized
that the hypolipidemic effects of ODA observed in vivo
[8] might be explained by activity at PPARs and so we
have tested the ability of ODA to occupy and transacti-
vate PPARs in vitro.
Results
PPAR transactivation
ODA at 10 and 50 μM evoked significant activation of
PPARα, PPARβ and PPARγ receptors in CHO cells over-
expressing these nuclear receptors (Figure 1). ODA appeared
to have the most marked, concentration-dependent effects
on PPARβ and PPARγ receptors, with 50 μM ODA evoking
responses in PPARβ- and PPARγ-expressing cells to 5.5-fold
and 3.2-fold control, respectively (Figure 1).
PPAR occupancy assays
Since whole cell reporter gene assays may be complicated
by metabolic conversion of putative ligands, we then tested
whether ODA was able to bind directly to PPARs, using se-
lective ligands for each receptor as positive controls. In each
case, the positive control evoked concentration-dependent
inhibition of fluorescent ligand binding to the ligand binding
domains of PPARα, PPARβ and PPARγ (Figure 2). Thus,
WY14643, GW0742 and rosiglitazone exhibited potenciesFigure 1 Assay of reporter gene activity in PPARα-, PPARβ- and PPAR
controls at PPARα, PPARβ and PPARγ were WY14643 (10 μM), GW0742 (1 μ
vehicle control. Data are means ± SEM from six different experiments cond
one-way ANOVA with Bonferroni’s post hoc test.(IC50 values) of 3.8×10
-7, 8.4×10-10 and 2.2×10-7 M at
PPARα, PPARβ and PPARγ, respectively.
In comparison, although ODA evoked concentration-
dependent displacement of fluorescent ligand from each
receptor binding site, displacement at PPARα and PPARβ
was incomplete at the highest concentration employed
(100 μM). The potency of ODA at PPARγ was estimated
at 3.8 x 10-5 M (Figure 2).
3T3-L1 differentiation
In the Oil Red O uptake-based assay, the positive con-
trol rosiglitazone (10 μM) was confirmed to increase
markedly the number of 3T3-L1 cells stained by the
lipid-sensitive dye (Figure 3). ODA (10–20 μM) was also
able to induce differentiation of 3T3-L1 cells into adipo-
cytes compared to the vehicle-treated controls, although
the extent of differentiation was less marked than in the
presence of rosiglitazone (Figure 3).
Discussion
In this study, we show that a further endocannabinoid-like
molecule, oleamide, is able to occupy and activate PPAR
nuclear receptors. As well as the phytocannabinoids THC
[19], the major psychoactive ingredient in Cannabis, and
cannabidiol [20], a number of endogenous cannabinoids
have been shown to activate PPARs. In particular, ananda-
mide, virodhamine, N-arachidonoyldopamine, noladin and
2-arachidonoylglycerol, as well as N-oleoylethanolamine
and N-palmitoylethanolamine, have been shown to activate
various members of the PPAR family [17,18].
Our results show that concentrations of ODA in the
mid-micromolar range were able to transactivate PPARα,
PPARβ and PPARγ nuclear receptors and this effect was
demonstrated to be concentration-dependent for PPARβ
and γ (Figure 1B and C). Interestingly, lower concentrations
of ODA (at 1 μM) appeared to significantly inhibit PPARγγ-transiently transfected Chinese hamster ovary cells. Positive
M) and rosiglitazone (1 μM), respectively, with DMSO (0.1%) as a
ucted in duplicate. * P< 0.05, ** P< 0.01, *** P< 0.001 assessed using
Figure 2 Assay of fluorescent ligand binding to ligand binding domains of PPARα, PPARβ and PPARγ. PPAR ligands employed as positive
controls alongside ODA were WY14643, GW0742 or rosiglitazone for PPARα, PPARβ and PPARγ, respectively. Data are means ± range of two
experiments (except WY14643, n = 1) conducted in sextuplicate.
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basal activation of these receptors by endogenous ligands in
CHO cells, for example as components of the serum. A
similar effect has been observed for the dietary polyunsatur-
ated fatty acids, docosahexaenoic acid and eicosapentaenoic
acid, which act as agonists at PPARs, but reduce the tonic
activation apparently evoked by endogenous higher affinity
agonists [21].
We were able to show directly that ODA was able to
occupy the ligand binding domain of all three receptors,
implying that the enzymatic generation of oleic acid
from ODA is not a simple explanation for the observed
effects. Of the three subtypes of PPAR, the potency of
ODA appeared highest at PPARγ (Figure 2), although
functional effects on PPARβ appeared higher in reporter
gene assays (Figure 1). This may be attributed to greater
amplification of PPARβ-evoked responses, or alterna-
tively, to background levels of PPARγ activity that were
relatively elevated.
The IC50 value (38 μM) of ODA at the PPARγ ligand
binding site is slightly higher than other endocannabi-
noid-like molecules reported to activate PPARγ. IC50
values for anandamide and 2-arachidonoylglycerol at
PPARγ are reported to be around 10 μM [22]. The phy-
tocannabinoid cannabidiol was reported to have a
potency of around 5 μM at PPARγ, while the IC50 valueFigure 3 Oil Red O staining following differentiation of 3T3-L1 cells in
DMSO), rosiglitazone (10 μM), ODA (10 μM) or ODA (20 μM). The pictufor ajulemic acid was around 600 nM [20]. However,
other saturated or unsaturated fatty acids that are
regarded as endogenous ligands for the three different
PPARs isotypes all have micromolar affinities to these
receptors, in line with their serum levels [14,15].
In order to address the issue of whether ODA
might be a physiological agonist at PPARγ, we investi-
gated the phenomenon of adipogenesis, which is a
well recognised consequence of PPARγ activation
[14,15]. Using 3T3-L1 cells, we observed that ODA at
10–20 μM was able to induce differentiation into adi-
pocytes (Figure 3).
The proposed novel site of action for ODA through
PPAR activation might be involved in some of the previ-
ously reported ODA effects. ODA has been reported to
induce vasorelaxation in the rat small mesenteric artery
in vitro through activation of an undefined receptor
which may be coupled to Ca2+-sensitive K+ channels and
Gi/o proteins [9]. However, the mechanism by which it eli-
cits vasorelaxation has not been fully explained. Central
effects of N-oleoylethanolamine (OEA) and N-palmitoy-
lethanolamine, two other endocannabinoid-related mole-
cules, have been demonstrated to be mediated through
PPARα activation [23-26]. OEA has also been reported
to elicit loss of appetite and to reduce body weight gain
in mice with a mechanism dependent on PPARα [23].to adipocytes in the presence of (from left to right) vehicle (0.1%
re is representative of three replicates.
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reduced infarct volume from middle cerebral artery occlu-
sion in wild-type, but not in PPARα-null, mice [27]. In
these two latter studies, OEA was shown to bind to the
ligand binding domain of PPARα and to transactivate
both PPARα and PPARβ, without activating PPARγ. Our
data show that ODA binds to all three PPAR LBDs, with
apparently highest affinity for PPARγ (Figure 2). OEA and
ODA share the same fatty acid chain, oleic acid, which,
together with a variety of other saturated and unsaturated
fatty acids, is one of the natural ligands of PPARα. By
contrast, PPARγ exhibits greater selectivity than PPARα
and is usually activated by polyunsaturated fatty acids
[14,15]. Even if the limiting factor for PPAR binding is
usually the length and saturation level of the fatty acid
chain, in this case the head residue would appear to
confer selectivity for PPARγ binding between OEA and
ODA. However, no direct evidence is available in the
literature of OEA binding (or not) to the ligand binding
domain of PPARγ.
The most relevant in vivo observation that might cor-
relate with ODA’s agonist activity at PPARs is the hypoli-
pidemic effect when administered in the diet to high fat-
fed hamsters [8]. In this report, ODA dose-dependently
reduced plasma triglyceride levels, as well as LDL chol-
esterol and liver triglyceride, without altering HDL chol-
esterol levels. This appears to be consistent with a site
of action through PPARs, at least in part, since agonists
at both PPARα and γ are observed to increase HDL
cholesterol levels, whilst reducing LDL cholesterol, as
well as plasma and liver triglycerides [15].
Conclusions
In summary, we have identified a novel site of action of
ODA, through PPARs. Our data indicate that ODA can
be regarded as a low affinity pan-PPAR ligand in vitro,
being able to transactivate all three isotypes of this
nuclear receptor family. ODA appeared to be most potent
as a ligand of PPARγ.
Methods
Chemicals
ODA was prepared by condensation of oleoyl chloride
(Sigma Chemical Company, Poole, UK) with saturated
ammonia solution (Fisher Scientific, Loughborough,
UK). Following purification over silica, TLC and NMR
analysis indicated a single product with undetectable
levels of oleic acid. WY14643 and GW0742 were pur-
chased from Tocris Cookson (Bristol, UK), while rosigli-
tazone was a kind donation from GlaxoSmithKline (UK).
Cell culture
CHO cells (originally obtained from ECACC, Salisbury,
UK) were incubated at 37°C and 5% CO2 in Dulbecco’sModified Medium (DMEM, Sigma, Poole, UK) supple-
mented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS, Sigma, Poole, UK), 2 mM L-glutamine (Sigma,
Poole, UK) and streptomycin/penicillin (50 μg ml-1 and
50 U ml-1, respectively, Sigma, Poole, UK).
Transactivation assay
A luciferase reporter construct under the control of
3xPPRE was transfected into CHO cells, together with
a pcDNA3.1 plasmid expressing the human PPARα,
PPARβ or PPARγ2 gene. Transient transfection of CHO
cells was carried out by the polyethyleneimine method
with the ratio nitrogen (N) to DNA phosphate (P) of N/
P = 15 as previously described [27]. 4 hours after trans-
fection, CHO cells were treated with either vehicle con-
trol (0.1% DMSO) or ligand, as indicated. 24 hours after
treatment, cells were harvested and lysed with Passive
Lysis Buffer (Promega, Wisconsin, USA) and luciferase
expression was monitored using the Luciferase Assay
System (Promega, Wisconsin, USA) and a luminometer
(TD-20/20, Turner Biosystems, California, USA). Data were
calculated as Relative Luciferase Units (RLU) mg-1 protein
and expressed as fold activation compared to control.
Protein quantification
Protein concentrations of the samples from the reporter
gene assay were titrated using Bio-Rad protein assay
(Bio-Rad, California, USA).
PPAR occupancy assays
Binding experiments to PPARα and PPARβ were carried
out with LanthascreenTM TR-FRET PPAR Competitive
Binding Assays (Invitrogen, California, USA) following
the manufacturer’s instructions. For PPARγ occupancy,
binding experiments were carried out with PolarscreenTM
PPAR Competitor Assay Green (Invitrogen, California,
USA) following the manufacturer’s instructions. The kits
use a fluorescent small molecule pan-PPAR ligand
(20nM for PPARα-β and 2.5nM for PPARγ) and human-
PPAR ligand binding domains. Fluorescent signal (340 nm
excitation and 495–520 nm emission; PPARα-β) and fluor-
escence polarization (485 nm excitation and 535 nm emis-
sion; PPARγ) were measured at room temperature in
black 384-well plates using an Envision MultiLabel plate
reader. Data are reported as percentage of the control.
3T3-L1 differentiation
3T3-L1 cells (originally obtained from ECACC, Salisbury,
UK) were grown to confluence in 6-well plates. 48 hours
after confluence, the culture medium was replaced and
supplemented with 1 μM dexamethasone and 5 μg mL-1
insulin (Sigma). After 48 hours, the culture medium was
replaced and supplemented with 5 μg mL-1 insulin and
vehicle (0.1% DMSO) or ligand, as indicated. Cells were
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and changing the medium 2–3 times per week. Once
differentiation occurred, cells were treated for 10 min-
utes with 4% formalin and incubated with Oil Red O at
room temperature for 1 hour. Images were taken from
the bottom of the wells with a scanner (Epson).
Statistical analysis
Statistical differences among treatments were assessed
using one-way ANOVA with Bonferroni’s post hoc
test. Displacement curves were fitted to the data using a
one-site competition binding model (GraphPad Prism,
California, USA).
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